查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1813971

类风湿性关节炎药物市场规模、份额和趋势分析报告：按分子、销售管道、地区和细分市场预测，2025-2033 年

Rheumatoid Arthritis Therapeutics Market Size, Share & Trends Analysis Report By Molecule (Pharmaceuticals, Biopharmaceuticals), By Sales Channel (Prescription, Over-the-Counter), By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

类风湿性关节炎治疗市场摘要

预计 2024 年全球类风湿性关节炎治疗市场价值为 257.6 亿美元，到 2033 年将达到 414.2 亿美元，2025 年至 2033 年的复合年增长率为 5.56%。

类风湿性关节炎(RA) 创新疗法的引入在推动市场成长方面发挥关键作用。

安进公司、辉瑞公司、基因泰克公司和诺华等主要企业相继推出赛妥珠单抗、Hyrimoz、Amgevita、Erelzi、Absola和利妥昔单抗等新型生物相似药，大大重塑了类风湿性关节炎（RA）治疗的格局。例如，2024年5月，勃林格殷格翰公司宣布美国食品药物管理局（FDA）核准Rituximab。同样在2024年5月，勃林格殷格翰宣布，美国食品药物管理局（克隆氏症了Humira的生物相似溃疡性大肠炎 （阿达木单抗-adbm）的僵直性脊椎炎，用于治疗多种慢性发炎性疾病，包括斑块型干癣、克隆氏干癣性关节炎、溃疡性结肠炎、牛皮癣、干癣关节炎、脓疱性Adalimumab核准、中度至重度斑块状干癣、非感染性葡萄膜炎。

同样，2023 年 1 月，诺华公司获得了欧洲药品管理局人用药品委员会 (CHMP) 对山德士 Hylimoz（Adalimumab）无柠檬酸盐高浓度製剂 (HCF) 的上市核准。此项核准将批准范围扩大到参考药物的所有适应症，包括 RA、葡萄膜炎、溃疡性大肠炎和斑块型干癣。这些新一代生物生技药品和生物相似药旨在作用于导致关节疼痛和发炎的特定免疫系统分子和受体，从而改善治疗效果。对此类有针对性和高效治疗的需求不断增长，预计将进一步推动 RA生物製药的进步。

近年来，类风湿性关节炎（RA）的治疗策略已转向能够诱导疾病缓解的新型分子。这项进展源于对类风湿性关节炎（RA）潜在机制的深入了解，并促进了生物目标和合成的缓解疾病的抗风湿药物 (DMARD) 的开发。虽然小分子 DMARD、皮质类固醇、镇痛药和非类固醇消炎剂(NSAID) 仍然是第一线治疗方法，但它们的主要目的是减缓疾病进展或抑制炎症，而非治癒 RA。此外，这些药物可能出现严重的副作用，包括胃肠道溃疡、免疫抑制、骨质疏鬆、噁心、细胞流失、疲劳、肝损伤、牛皮癣以及感染疾病风险增加。

目录

第一章调查方法与范围

第二章执行摘要

第三章类类风湿性关节炎关节炎药物市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章类风湿性关节炎药物市场：分子业务分析

  • 2024 年及 2033 年分子市场份额
  • 分子细分仪表板
  • 2021 年至 2033 年按分子分類的市场规模、预测与趋势分析
  • 製药
  • 生物製药

第五章类风湿性关节炎治疗市场：销售管道业务分析

  • 2024年及2033年销售管道市场份额
  • 销售管道细分仪表板
  • 2021-2033 年按销售管道分類的市场规模、预测与趋势分析
  • 处方笺
  • 非处方药

第六章类风湿性关节炎治疗市场：区域估计与趋势分析

  • 2024 年及 2033 年区域市占率分析
  • 区域市场仪表板
  • 2021-2033 年市场规模与预测趋势分析：
  • 北美洲
    • 按国家/地区，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • AbbVie, Inc.
    • Boehringer Ingelheim International GmbH
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Pfizer, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • UCB SA
    • Johnson &Johnson Services, Inc.
    • Amgen, Inc.
    • Lilly（Eli Lilly and Company）
Product Code: GVR-2-68038-313-3

Rheumatoid Arthritis Therapeutics Market Summary

The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033, growing at a CAGR of 5.56% from 2025 to 2033. The introduction of innovative therapeutics for rheumatoid arthritis (RA) is playing a key role in boosting market growth.

The launch of new biosimilars such as Cyltezo, Hyrimoz, Amgevita, Erelzi, Avsola, and Rituximab by leading pharmaceutical companies including Amgen Inc., Pfizer Inc., Genentech, Inc., and Novartis has significantly reshaped the RA treatment landscape. For instance, In May 2024, Boehringer Ingelheim announced that the U.S. Food and Drug Administration had approved a high-concentration, citrate-free formulation of Cyltezo (adalimumab-adbm) the company's interchangeable biosimilar to Humira for treating multiple chronic inflammatory diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, hidradenitis suppurativa, ankylosing spondylitis, moderate-to-severe plaque psoriasis, and non-infectious uveitis.

In a similar development, January 2023 saw Novartis AG secure marketing authorization from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for Sandoz's citrate-free, high-concentration formulation (HCF) of Hyrimoz (adalimumab). This approval extends to all indications of the reference medicine, including RA, uveitis, ulcerative colitis, and plaque psoriasis. These next-generation biologics and biosimilars are designed to act on specific immune system molecules or receptors responsible for joint pain and inflammation, resulting in improved treatment outcomes. Rising demand for such targeted and efficient therapies is expected to further drive advancements in biologic treatments for RA.

In recent years, RA treatment strategies have shifted toward newer molecules capable of inducing disease remission. This evolution stems from a deeper understanding of RA's underlying mechanisms, leading to the creation of targeted biologic and synthetic disease-modifying antirheumatic drugs (DMARDs). While first-line treatment still includes small-molecule DMARDs, corticosteroids, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), these options primarily slow disease progression and manage inflammation rather than curing the condition. Moreover, they can cause notable side effects, such as gastrointestinal ulcers, immunosuppression, osteoporosis, nausea, cytopenia, fatigue, skin rashes, liver damage, psoriasis, and an increased risk of infections.

Global Rheumatoid Arthritis Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global rheumatoid arthritis therapeutics market report based on molecule, sales channel, and region:

  • Molecule Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Glucocorticoids
  • Biopharmaceuticals
    • Biologics
    • TNF-a antagonists
    • T-cell inhibitors
    • CD20 antigen
    • JAK inhibitors
    • Anti-IL6 biologics
    • Biosimilars
    • CD20 antigen
    • TNF-a antagonists
  • Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Prescription
  • Over-the-Counter (OTC)
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Molecule
    • 1.2.2. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rheumatoid Arthritis Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Rheumatoid Arthritis Therapeutics Market: Molecule Business Analysis

  • 4.1. Molecule Market Share, 2024 & 2033
  • 4.2. Molecule Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Molecule, 2021 to 2033 (USD Million)
  • 4.4. Pharmaceuticals
    • 4.4.1. Pharmaceuticals Market, 2021 - 2033 (USD Million)
    • 4.4.2. NSAIDs
      • 4.4.2.1. NSAIDs Market, 2021 - 2033 (USD Million)
    • 4.4.3. Analgesics
      • 4.4.3.1. Analgesics Market, 2021 - 2033 (USD Million)
    • 4.4.4. DMARDs
      • 4.4.4.1. DMARDs Market, 2021 - 2033 (USD Million)
    • 4.4.5. Glucocorticoids
      • 4.4.5.1. Glucocorticoids Market, 2021 - 2033 (USD Million)
  • 4.5. Biopharmaceuticals
    • 4.5.1. Biopharmaceuticals Market, 2021 - 2033 (USD Million)
    • 4.5.2. Biologics
      • 4.5.2.1. Biologics Market, 2021 - 2033 (USD Million)
      • 4.5.2.2. TNF-a antagonists
        • 4.5.2.2.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)
      • 4.5.2.3. T-cell inhibitors
        • 4.5.2.3.1. T-cell inhibitors Market, 2021 - 2033 (USD Million)
      • 4.5.2.4. CD20 antigen
        • 4.5.2.4.1. CD20 antigen Market, 2021 - 2033 (USD Million)
      • 4.5.2.5. JAK inhibitors
        • 4.5.2.5.1. JAK inhibitors Market, 2021 - 2033 (USD Million)
      • 4.5.2.6. Anti-IL6 biologics
        • 4.5.2.6.1. Anti-IL6 biologics Market, 2021 - 2033 (USD Million)
    • 4.5.3. Biosimilars
      • 4.5.3.1. Biosimilars Market, 2021 - 2033 (USD Million)
      • 4.5.3.2. CD20 antigen
        • 4.5.3.2.1. CD20 antigen Market, 2021 - 2033 (USD Million)
      • 4.5.3.3. TNF-a antagonists
        • 4.5.3.3.1. TNF-a antagonists Market, 2021 - 2033 (USD Million)

Chapter 5. Rheumatoid Arthritis Therapeutics Market: Sales Channel Business Analysis

  • 5.1. Sales Channel Market Share, 2024 & 2033
  • 5.2. Sales Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
  • 5.4. Prescription
    • 5.4.1. Prescription Market, 2021 - 2033 (USD Million)
  • 5.5. Over-the-Counter (OTC)
    • 5.5.1. Over-the-Counter (OTC) Market, 2021 - 2033 (USD Million)

Chapter 6. Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. Canada Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. UK Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Brazil Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. Argentina Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Rheumatoid Arthritis Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. AbbVie, Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Molecule Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Boehringer Ingelheim International GmbH
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Molecule Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Novartis AG
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Molecule Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Regeneron Pharmaceuticals Inc.
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Molecule Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Pfizer, Inc.
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Molecule Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Bristol-Myers Squibb Company
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Molecule Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. F. Hoffmann-La Roche Ltd.
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Molecule Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. UCB S.A.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Molecule Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Johnson & Johnson Services, Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Molecule Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. Amgen, Inc.
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Molecule Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Lilly (Eli Lilly and Company)
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Molecule Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 4 Global rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 5 North America rheumatoid arthritis therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 6 North America rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 7 North America rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 8 U.S. rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 9 U.S. rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 10 Canada rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 11 Canada rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 12 Mexico rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 13 Mexico rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 14 Europe rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 15 Europe rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 16 Europe rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 17 UK rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 18 UK rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 19 Germany rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 20 Germany rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 21 France rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 22 France rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 23 Italy rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 24 Italy rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 25 Spain rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 26 Spain rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 27 Norway rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 28 Norway rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 29 Sweden rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 30 Sweden rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 31 Denmark rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 32 Denmark rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 33 Asia Pacific rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 34 Asia Pacific rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 35 Asia Pacific rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 36 Japan rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 37 Japan rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 38 China rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 39 China rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 40 India rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 41 India rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 42 Australia rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 43 Australia rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 44 South Korea rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 45 South Korea rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 46 Thailand rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 47 Thailand rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 48 Latin America rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Latin America rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 50 Latin America rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 51 Brazil rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 52 Brazil rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 53 Argentina rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 54 Argentina rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 55 Middle East & Africa rheumatoid arthritis therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 56 Middle East & Africa rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 57 Middle East & Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 58 South Africa rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 59 South Africa rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 60 Saudi Arabia rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 61 Saudi Arabia rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 62 UAE rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 63 UAE rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)
  • Table 64 Kuwait rheumatoid arthritis therapeutics market, by molecule, 2021 - 2033 (USD Million)
  • Table 65 Kuwait rheumatoid arthritis therapeutics market, by sales channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Rheumatoid arthritis therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and molecule outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Rheumatoid arthritis therapeutics market dynamics
  • Fig. 12 Rheumatoid arthritis therapeutics market: Porter's five forces analysis
  • Fig. 13 Rheumatoid arthritis therapeutics market: PESTLE analysis
  • Fig. 14 Molecule market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 15 Biopharmaceuticals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 16 Biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 17 TNF-a antagonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 18 T-cell inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 19 CD20 antigen market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 20 JAK inhibitors market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 21 Anti-IL6 biologics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 22 Biosimilars market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 23 CD20 antigen market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 24 TNF-a antagonists market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 25 Pharmaceuticals market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 26 NSAIDs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 27 Analgesics market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 28 DMARDs market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 29 Glucocorticoids market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 30 Rheumatoid arthritis therapeutics: Sales channel outlook and key takeaways
  • Fig. 31 Rheumatoid arthritis therapeutics market: Sales channel market movement analysis
  • Fig. 32 Prescription market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 33 Over-the-Counter (OTC) market estimates and forecast, 2021 - 2033 (USD Million)
  • Fig. 34 Rheumatoid arthritis therapeutics market revenue, by region
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 37 US country dynamics
  • Fig. 38 US rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 Europe rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Asia Pacific rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 Latin America rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 MEA rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 85 Kuwait country dynamics
  • Fig. 86 Kuwait rheumatoid arthritis therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework